Pharmacogenetics of Antidepressant Response

  • A. Serretti
  • A. Drago
  • Michael N Liebman


Nowadays, the efficacy of antidepressant treatment and the profile of side effects are not predictable: sociodemographic and clinical variables have not provided clinicians with consistent support. Emerging evidence reports promising results from the genetic approach: pharmacogenetics identifies which genetic variations are associated with drug treatment outcome. Both pharmacodynamic and pharmacokinetic key genes have been investigated, and even though consistent conclusions are yet to come, several lines of evidence have led researchers to assume a promising future of effective pharmacogenetic-based pretreatment assessment. The most important antidepressant pharmacogenetic results in this field are reviewed in this chapter and future research lines are proposed.


Major Depressive Disorder Clock Gene Corticotropin Release Hormone Novelty Seek Antidepressant Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Serotonin receptor 1 A


Serotonin receptor 2A


Serotonin receptor 6


ATP-binding cassette subfamily B member 1






Beta1 adrenoceptor


Beta2 adrenoceptor


Circadian Locomotor Output Cycles Kaput


Catechol-O-methyl transferase




Corticotropin releasing hormone


Dopamine (receptor) type 2


Dopamine (receptor) type 3


Dopamine (receptor) type 4


(gene for the) dopamine receptor D 2


(gene for the) dopamine receptor D 3


(gene for the) dopamine receptor D 4




Lysergic acid diethylamide


Mono amino oxidase A


Membrane-bound COMT


Major depressive disorder


Norepinephrine transporter


Nitric oxide synthase


Obsessive compulsive disorder


Single nucleotide polymorphism


Selective Serotonin Reuptake Inhibitors


Soluble form of COMT


Tricyclic antidepressants


Food and Drug Administration (United States)


Variable number tandem repeat


  1. Akin, D., et al. 2005. Signal transduction abnormalities in melancholic depression. Int J Neuropsychopharmacol, 8(1):5–16.PubMedGoogle Scholar
  2. Albert, P.R. Lemonde, S. 2004. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist, 10(6):575–593.PubMedGoogle Scholar
  3. Anguelova, M., Benkelfat, C. Turecki, G. 2003. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatr, 8(7):646–653.Google Scholar
  4. Anisman, H., et al. 1999. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatr, 46(12):1649–1655.Google Scholar
  5. Anisman, H., Kokkinidis, L. Merali, Z. 2002. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun, 16(5):544–556.PubMedGoogle Scholar
  6. Arias, B., et al. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. In World Federation of societies of Biological Psychiatry. 2001. Berlin, Germany: The World Journal of Biological Psychiatry.Google Scholar
  7. Arias, B., et al. 2003. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol, 23(6):563–567.PubMedGoogle Scholar
  8. Arias, B., et al. 2005. Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol, 19(2):166–172.PubMedGoogle Scholar
  9. Arias, B., et al. 2006. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord, 90(2–3):251–256.PubMedGoogle Scholar
  10. Arif, E., et al. 2007. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta, 382(1–2):37–42.PubMedGoogle Scholar
  11. Arinami, T., et al. 1996. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatr, 40(11):1122–1127.Google Scholar
  12. Auron, P.E., et al. 1985. Human and murine interleukin 1 possess sequence and structural similarities. J Mol Cell Immunol, 2(3):169–177.PubMedGoogle Scholar
  13. Baghai, T., et al. 2002. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett, 328(3):299–303.PubMedGoogle Scholar
  14. Baghai, T., et al. 2003. Influence of a functional polymorphism within the angiotensin I-converting enzyme gene on partial sleep deprivation in patients with major depression. Neurosci Lett, 339(3):223–226.PubMedGoogle Scholar
  15. Baghai, T.C., et al. 2001. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatr, 6(3):258–259.Google Scholar
  16. Baghai, T.C., et al. 2004. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett, 363(1):38–42.PubMedGoogle Scholar
  17. Balant-Gorgia, A.E., et al. 1982. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr, 232(3):215–222.PubMedGoogle Scholar
  18. Ballaz, S.J., Akil, H. Watson, S.J. 2007. Analysis of 5-HT6 and 5-HT7 receptor gene expression in rats showing differences in novelty-seeking behavior. Neuroscience, 147(2):428–438.PubMedGoogle Scholar
  19. Bartlett, C.W., et al. 2005. Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int J Dev Neurosci, 23(2–3):221–234.PubMedGoogle Scholar
  20. Bauer, M., et al. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatr, 3(1):5–43.Google Scholar
  21. Baumann, P., et al. 1986. Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. Int Clin Psychopharmacol, 1(2):89–101.Google Scholar
  22. Bellivier, F., et al. 2002. Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci Lett, 334(1):17–20.PubMedGoogle Scholar
  23. Bellivier, F., Chaste, P. Malafosse, A. 2004. Association between the TPH gene A218C polymorphism and suicidal behavior: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet, 124(1):87–91.Google Scholar
  24. Benedetti, F., et al. 2003a. Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatr Res, 118(3):241–247.Google Scholar
  25. Benedetti, F., et al. 2003b. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet, 123B(1):23–26.Google Scholar
  26. Benjamin, J., et al. 1996. Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet, 12(1):81–84.PubMedGoogle Scholar
  27. Bertilsson, L., et al. 2002. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol, 53(2):111–122.PubMedGoogle Scholar
  28. Bhagwagar, Z., et al. 2006. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with (11)C]MDL 100,907 Am J Psychiatr, 163(9):1580–1587.PubMedGoogle Scholar
  29. Bialecka, M., et al. 2007. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson’s disease. Parkinsonism Relat Disord, 13(4):224–229.PubMedGoogle Scholar
  30. Binder, E., et al. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet, 36(12):1319–1325.PubMedGoogle Scholar
  31. Binder, E.B. Holsboer, F. 2006. Pharmacogenomics and antidepressant drugs. Ann Med, 38(2):82–94.PubMedGoogle Scholar
  32. Bishop, J.R., et al. 2006. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology, 31(10):2281–2288.PubMedGoogle Scholar
  33. Bobb, A.J., et al. 2005. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet, 132(1):109–125.Google Scholar
  34. Bondy, B., et al. 2005. Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog Neuropsychopharmacol Biol Psychiatr, 29(6):1094–1099.Google Scholar
  35. Bondy, B., Buettner, and A. Zill, 2006. Genetics of suicide. Mol Psychiatr, 11(4):336–351.Google Scholar
  36. Brady, L.S., et al. 1992. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res, 572(1–2):117–125.PubMedGoogle Scholar
  37. Brockmoller, J., Meineke, I. Kirchheiner, J. 2007. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther, 81(5):699–707.PubMedGoogle Scholar
  38. Brosen, K. Naranjo, C. 2001. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol, 11(4):275–283.PubMedGoogle Scholar
  39. Brosen, K., Hansen, J. Nielsen, K. 1993. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol, 44(4):344–355.Google Scholar
  40. Brunner, H.G., et al. 1993. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science, 262(5133):578–580.PubMedGoogle Scholar
  41. Bruss, M., et al. 1993. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet, 91(3):278–280.PubMedGoogle Scholar
  42. Campbell, D., et al. 1997. Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. Genet Test, 1(4):297–299.PubMedGoogle Scholar
  43. Caspi, A., et al. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301(5631):386–389.PubMedGoogle Scholar
  44. Charlier, C., et al. 2003. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit, 25(6):738–742.PubMedGoogle Scholar
  45. Chen, G., et al. 1999. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med, 61(5):599–617.PubMedGoogle Scholar
  46. Chen, K., et al. 1992. The human 5-HT2 receptor is encoded by a multiple intron-exon gene. Brain Res Mol Brain Res, 14(1–2):20–26.PubMedGoogle Scholar
  47. Chiavegatto, S., et al. 2001. Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. Proc Natl Acad Sci U S A, 98(3):1277–1281.PubMedGoogle Scholar
  48. Choi, M., et al. 2005. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology, 52:155–162.PubMedGoogle Scholar
  49. Choi, M.J., et al. 2006. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res, 1118(1):176–182.PubMedGoogle Scholar
  50. Clark, J.A., et al. 2005. Differential hormonal regulation of tryptophan hydroxylase-2 mRNA in the murine dorsal raphe nucleus. Biol Psychiatr, 57(8):943–946.Google Scholar
  51. Courtet, P., et al. 2001. Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene. Mol Psychiatr, 6(3):338–341.Google Scholar
  52. Craddock, N., O’Donovan, M.C. Owen, M.J. 2006. Genes for Schizophrenia and Bipolar Disorder? Implications for Psychiatric Nosology. Schizophr Bull, 32(1):9–16.PubMedGoogle Scholar
  53. Craig, S.P., et al. 1991. Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3–p14 by in situ hybridization. Cytogenet Cell Genet, 56(3–4):157–159.PubMedGoogle Scholar
  54. Cramer, J.A. Rosenheck, R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49:196–201.PubMedGoogle Scholar
  55. Crissman, A.M., Makhay, M.M. O’Donnell, J.M. 2001. Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl), 154(1):70–75.Google Scholar
  56. Crowley, J.J., et al. 2006. Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology, 31(11):2433–2442.PubMedGoogle Scholar
  57. Cusin, C., et al. 2001. Influence of 5-HTTLPR and TPH Variants on Illness Time Course in Mood Disorders. J Psychiatric Res, 35(4):217–223.Google Scholar
  58. Cusin, C., et al. 2002. Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int Neuropsychopharmacol, 5:27–35.Google Scholar
  59. Dalen, P., et al. 1998. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther, 63(4):444–452.PubMedGoogle Scholar
  60. Danish University Antidepressant, G., Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clin Pharmacol Ther, 1999. 66(2):152–165.Google Scholar
  61. Lara, C.L., de et al. 2007. Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression. Biol Psychiatr, 62(1):72–80.Google Scholar
  62. Leon, J., de 2007. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol, 27(3):241–245.PubMedGoogle Scholar
  63. Luca, V., De et al. 2003. Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J, 3(5):297–299.PubMedGoogle Scholar
  64. Dentino, A.N., et al. 1999. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc, 47(1):6–11.PubMedGoogle Scholar
  65. Giovine, F., Di Takhsh, E. Blakemore, A. 1992. Single base polymorphism at -511 in the human interleukin-1 gene (IL1). Hum Mol Genet, 1:450.PubMedGoogle Scholar
  66. Dick, F., et al., Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med, 2007.Google Scholar
  67. Dunn, A.J., 1988. Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone. Life Sci, 43(5):429–435.PubMedGoogle Scholar
  68. Durham, L.K., et al. 2004. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl), 174(4):525–529.Google Scholar
  69. Duric, G., et al. 2007. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease] Vojnosanit Pregl,64(1):25–30.PubMedGoogle Scholar
  70. Ebstein, R.P., et al. 1996. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet, 12(1):78–80.PubMedGoogle Scholar
  71. Eichelbaum, M., Fromm, M.F. Schwab, M. 2004. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit, 26(2):180–185.PubMedGoogle Scholar
  72. El-Omar, E.M., et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404(6776):398–402.PubMedGoogle Scholar
  73. Entsuah, A.R., Huang, H. Thase, M.E. 2001. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatr, 62(11):869–77.Google Scholar
  74. Eyada, T.K., et al. 2007. Study of genetic polymorphism of xenobiotic enzymes in acute leukemia. Blood Coagul Fibrinolysis, 18(5):489–495.PubMedGoogle Scholar
  75. Feinn, R., Nellissery, M. Kranzler, H.R. 2005. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet, 133(1):79–84.Google Scholar
  76. Fojo, A.T., et al. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A, 84(1):265–269.PubMedGoogle Scholar
  77. Francke, U. Foellmer, B.E. 1989. The glucocorticoid receptor gene is in 5q31-q32 [corrected]. Genomics, 4(4):610–612.PubMedGoogle Scholar
  78. Fuke, S., et al. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J, 1(2):152–156.PubMedGoogle Scholar
  79. Fukui, N., et al. 2007. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit, 29(2):185–189.PubMedGoogle Scholar
  80. Garriock, H., et al. 2005. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatr, 10(11):976–977.Google Scholar
  81. Garriock, H.A., et al. 2006. Number of risk genotypes is a risk factor for major depressive disorder: a case control study. Behav Brain Funct, 2:24.PubMedGoogle Scholar
  82. Gaysina, D., et al. 2006. The serotonin transporter gene: polymorphism and haplotype analysis in Russian suicide attempters. Neuropsychobiology, 54(1):70–74.PubMedGoogle Scholar
  83. Gelernter, J., et al. 1997. D4 dopamine-receptor (DRD4) alleles and novelty seeking in substance-dependent, personality-disorder, and control subjects. Am J Hum Genet, 61(5):1144–1152.PubMedGoogle Scholar
  84. Gemma, C., et al. 1997. Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol, 272(Pt 2):R601–R606.Google Scholar
  85. Gemma, C., Imeri, L. Opp, M.R. 2003. Serotonergic activation stimulates the pituitary-adrenal axis and alters interleukin-1 mRNA expression in rat brain. Psychoneuroendocrinology, 28(7):875–884.PubMedGoogle Scholar
  86. Geracitano, R., et al. 2006. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons. Ann N Y Acad Sci, 1074:320–329.PubMedGoogle Scholar
  87. Giros, B., et al. 1992. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol, 42(3):383–390.PubMedGoogle Scholar
  88. Golab-Janowska, M., et al. 2007. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer’s disease and Parkinson’s disease with dementia. Neurol Neurochir Pol, 41(2):113–121.PubMedGoogle Scholar
  89. Gold, P.W. Chrousos, G.P. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatr, 7(3):254–275.Google Scholar
  90. Grasmader, K., et al. 2004. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol, 60(5):329–336.PubMedGoogle Scholar
  91. Grossman, M.H., Emanuel, B.S. Budarf, M.L. 1992. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1–q11.2. Genomics, 12(4):822–825.PubMedGoogle Scholar
  92. Guasch, J.F., Bertina, R.M. Reitsma, P.H. 1996. Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine, 8(8):598–602.PubMedGoogle Scholar
  93. Gutierrez, B., et al. 1998. Variability in the serotonin transporter gene and increased risk for major depression with melancholia. Hum Gen, 103(3):319–322.Google Scholar
  94. Gutknecht, L., et al. 2007. Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. Int J Neuropsychopharmacol, 10(3):309–320.PubMedGoogle Scholar
  95. Hahn, M.K., Mazei-Robison, M.S. Blakely, R.D. 2005. Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol, 68(2):457–466.PubMedGoogle Scholar
  96. Ham, B., et al. 2005. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet, 15(4):229–301.Google Scholar
  97. Ham, B.J., et al. 2007. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatr, 31(1):104–107.Google Scholar
  98. Heils, A., et al. 1996. Allelic variation of human serotonin trasporter gene expression. J Neurochem, 66(6):2621–2624.PubMedGoogle Scholar
  99. Hemeryck, A. Belpaire, F.M. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab, 3(1):13–37.PubMedGoogle Scholar
  100. Hemrick-Luecke, S.K., Snoddy, H.D. Fuller, R.W. 1994. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci, 55(7):479–483.PubMedGoogle Scholar
  101. Herbert, T.B. Cohen, S. 1993. Depression and immunity: a meta-analytic review. Psychol Bull, 113(3):472–486.PubMedGoogle Scholar
  102. Holmes, A., Murphy, D.L. Crawley, J.N. 2003a. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatr, 54(10):953–959.Google Scholar
  103. Holmes, A., et al. 2003b. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology, 28(12):2077–2088.Google Scholar
  104. Holsboer, F., 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23(5):477–501.PubMedGoogle Scholar
  105. Hong, C.J., Wang, Y.C. Tsai, S.J. 2002. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm, 109(9):1209–1214.PubMedGoogle Scholar
  106. Hong, C.J., et al. 2006. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J, 6(1):27–33.PubMedGoogle Scholar
  107. Hranilovic, D., et al. 2004. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatr, 55(11):1090–1094.Google Scholar
  108. Hrdina, P.D. Vu, T.B. 1993. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse, 14(4):324–331.PubMedGoogle Scholar
  109. Hu, X., et al. 2005. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res, 29(1):8–16.PubMedGoogle Scholar
  110. Hu, X.Z., et al. 2007. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatr, 64(7):783–792.PubMedGoogle Scholar
  111. Ito, K., et al. 2002. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatr Res, 111(2–3):235–239.Google Scholar
  112. Itokawa, M., et al. 1993. A structural polymorphism of human dopamine D2 receptor, D2(Ser311‐‐>Cys). Biochem Biophys Res Commun, 196(3):1369–1375PubMedGoogle Scholar
  113. Jezova, D., et al. 1998. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol, 10(1):67–72.PubMedGoogle Scholar
  114. Jonsson, E.G., et al. 1997. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatr & Clin Neurosci, 247(6):297–302.Google Scholar
  115. Joyce, P.R., et al. 2003. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol, 6(4):339–346.PubMedGoogle Scholar
  116. Kabiersch, A., et al. 1988. Interleukin-1 induces changes in norepinephrine metabolism in the rat brain. Brain Behav Immun, 2(3):267–274.PubMedGoogle Scholar
  117. Kang, R.H., et al., Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatr, 2007.Google Scholar
  118. Kato, M., et al. 2005. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol, 20(3):151–156.PubMedGoogle Scholar
  119. Kato, M., et al. 2006. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients Neuropsychobiology, 53(4):186–195.PubMedGoogle Scholar
  120. Katzenberg, D., et al. 1998. A CLOCK polymorphism associated with human diurnal preference. Sleep, 21(6):569–576.PubMedGoogle Scholar
  121. Kehne, J.H., 2007. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets, 6(3):163–182.PubMedGoogle Scholar
  122. Kiecolt-Glaser, J.K. Glaser, R. 2002. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res, 53(4):873–876.PubMedGoogle Scholar
  123. Kim, C.H., et al. 2006. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A, 103(50):19164–19169.PubMedGoogle Scholar
  124. Kim, D.K., et al. 2000. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport, 11(1):215–219.PubMedGoogle Scholar
  125. Kim, H., et al. 2006. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. Jama, 296(13):1609–1618.PubMedGoogle Scholar
  126. Kim, S.W., Park, S.Y. Hwang, O. 2002. Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Mol Pharmacol, 61(4):778–785.PubMedGoogle Scholar
  127. Kirchheiner, J., et al. 2001. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand, 104(3):173–192.PubMedGoogle Scholar
  128. Kirchheiner, J., et al. 2004. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol, 24(6):647–652.PubMedGoogle Scholar
  129. Kirchheiner, J., Grundemann, D. Schomig, E. 2006a. Contribution of allelic variations in transporters to the phenotype of drug response. J Psychopharmacol, 20(Suppl 4):27–32.Google Scholar
  130. Kirchheiner, J., et al., A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J, 2006b.Google Scholar
  131. Kirchheiner, J., et al. 2007. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J, 7(1):48–55.PubMedGoogle Scholar
  132. Kirigiti, P., et al. 2000. Rat beta 1-adrenergic receptor regulatory region containing consensus AP-2 elements recognizes novel transactivator proteins. Mol Cell Biol Res Commun, 3(3):181–192.PubMedGoogle Scholar
  133. Kishimoto, J., et al. 1992. Localization of brain nitric oxide synthase (NOS) to human chromosome 12. Genomics, 14(3):802–804.PubMedGoogle Scholar
  134. Kobilka, B.K., et al. 1987. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature, 329(6134):75–79.PubMedGoogle Scholar
  135. Kohen, R., et al. 1996. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem, 66(1):47–56.PubMedGoogle Scholar
  136. Kraft, J., et al. 2005. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatr, 58(374–381).Google Scholar
  137. Kraft, J.B., et al. 2007. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatr, 61(6):734–742.Google Scholar
  138. Kramer, M.S., et al. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281(5383):1640–1645.PubMedGoogle Scholar
  139. Kremer, I., et al. 2005. Association of the serotonin transporter gene with smoking behavior. Am J Psychiatr, 162(5):924–930.PubMedGoogle Scholar
  140. Lachman, H.M., et al. 1996. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet, 67(5):468–472.PubMedGoogle Scholar
  141. Lachman, H.M., et al. 1997. Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am J Med Genet, 74:121–128.PubMedGoogle Scholar
  142. Laika, B., Leucht, S. Steimer, W. 2006. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem, 52(5):893–895.PubMedGoogle Scholar
  143. Landen, M. Thase, M.E. 2006. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol Bull, 39(1):147–166.PubMedGoogle Scholar
  144. Lavandera, J.V., et al. 2006. CYP2D6 polymorphisms in patients with porphyrias. Mol Med, 12(9–10):259–263.PubMedGoogle Scholar
  145. Beau, M.M. Le Rowley, J.D. 1986. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet, 15:1–54.PubMedGoogle Scholar
  146. Lee, H.J., et al. 2004. Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J, 4(1):29–33.PubMedGoogle Scholar
  147. Lee, M.S., et al. 2004. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet, 14(2):111–115.PubMedGoogle Scholar
  148. Lee, S., et al. 2005. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatr Clin Neurosci, 59:140–145.Google Scholar
  149. Lee, S.Y., et al. 2006. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit, 28(3):382–387.PubMedGoogle Scholar
  150. Lemonde, S., et al. 2003. Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J Neurosci, 23(25):8788–8799.PubMedGoogle Scholar
  151. Lemonde, S., et al. 2004. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Psychopharmacology (Berl), 24:24.Google Scholar
  152. Lemos, M.C., et al., Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf), 2007.Google Scholar
  153. Lesch, K.P., et al. 1994. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect, 95(2):157–162.PubMedGoogle Scholar
  154. Levine, M.A., et al. 1990. Molecular cloning of beta-3 subunit, a third form of the G protein beta-subunit polypeptide. Proc. Nat. Acad. Sci U S A, 87:2329–2333.Google Scholar
  155. Li, Z., Inenaga, K. Yamashita, H. 1993. GABAergic inputs modulate effects of interleukin-1 beta on supraoptic neurones in vitro. Neuroreport, 5(2):181–183.PubMedGoogle Scholar
  156. Licinio, J. Wong, M.L. 1999. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatr, 4(4):317–327.Google Scholar
  157. Licinio, J., et al. 2004. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatr, 9:1075–1082.Google Scholar
  158. Lim, J.E., et al. 2007. Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatr, 12(5):491–501.Google Scholar
  159. Lin, J.H. Lu, A.Y. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet, 35(5):361–390.PubMedGoogle Scholar
  160. Linthorst, A.C., et al. 1994. Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology, 135(2):520–532.PubMedGoogle Scholar
  161. Liu, Z., et al. 2007. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett, 414(2):155–158.PubMedGoogle Scholar
  162. Liu, Z.C., Luo, X.N. Wang, G.H. 2002. Corticotropin-releasing factor andmajor depression. Foreign Med Sci: Section of Psychiatry , 2:156–158.Google Scholar
  163. Lopez de Lara, C., et al. 2006. STin2 variant and family history of suicide as significant predictors of suicide completion in major depression. Biol Psychiatr, 59(2):114–120.Google Scholar
  164. MacKenzie, A. Quinn, J. 1999. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A, 96(26):15251–15255.PubMedGoogle Scholar
  165. Maes, M. and H.Y. Meltzer, The serotonin hypothesis of major depression, in Psychopharmacology: The fourth generation of progress, F.E. Bloom and D.J. Kupfer, Editors. 1995, Raven Press: New York, pp 933–944.Google Scholar
  166. Maes, M.,et al. 1993. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatr, 150(8):1189–1193.PubMedGoogle Scholar
  167. Maj, J., et al. 1996. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl), 127(1):73–82.Google Scholar
  168. Malhotra, A.K. Goldman, D. 2000. The dopamine D(4) receptor gene and novelty seeking. Am J Psychiatr, 157(11):1885–1886.PubMedGoogle Scholar
  169. Manev, H. Uz, T. 2006. Clock genes: influencing and being influenced by psychoactive drugs. Trends Pharmacol Sci, 27(4):186–189.PubMedGoogle Scholar
  170. Mannisto, Kaakkola, S. 2005. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev, 51(4):593–628.Google Scholar
  171. Manuck, S.B., et al. 2000. A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatr Res, 95(1):9–23.Google Scholar
  172. Marsh, S. McLeod, H.L. 2007. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother, 8(2):119–127.PubMedGoogle Scholar
  173. Masand, P.S., 2003. Tolerability and adherence issues in antidepressant therapy. Clin Ther, 25(8):2289–2304.PubMedGoogle Scholar
  174. Mason, D.A., et al. 1999. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem, 274(18):12670–12674.PubMedGoogle Scholar
  175. Matsushita, S., et al. 2004. Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet, 128(1):114–117.Google Scholar
  176. McMahon, F.J., et al. 2006. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet, 78(5):804–814.PubMedGoogle Scholar
  177. Meyer, J.H., et al. 2001. The effect of paroxetine on 5-HT2A receptors in depression: an [18F]Setoperone PET imaging study. Am J Psychiatr, 158:78–85.PubMedGoogle Scholar
  178. Michelson, D., et al. 1997. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab, 82(8):2601–2606.PubMedGoogle Scholar
  179. Mignone, F., et al., Untranslated regions of mRNAs. Genome Biol, 2002. 3(3):REVIEWS0004.Google Scholar
  180. Miller, L.G., et al. 1991. Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain. Mol Pharmacol, 39(2):105–108.PubMedGoogle Scholar
  181. Minov, C., et al. 2001. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett, 303(2):119–122.PubMedGoogle Scholar
  182. Mitchell, A.J., 2006. Two-week delay in onset of action of antidepressants: new evidence. Br J Psychiatr, 188:105–106.Google Scholar
  183. Mitchell, E.S., Sexton, T. Neumaier, J.F. 2007. Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology, 32(7):1520–1530.PubMedGoogle Scholar
  184. Moncrieff, J. Kirsch, I. 2005. Efficacy of antidepressants in adults. BMJ, 331: (7509):551–557.Google Scholar
  185. Mossner, R., et al. 2006. Aberrant accumulation of serotonin in dopaminergic neurons. Neurosci Lett, 401(1–2):49–54.PubMedGoogle Scholar
  186. Muller, D.J., et al. 2000. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase-A promoter. in Eighth World Congress on Psychiatric Genetics. Neuropsychiatric Genetics, Wiley-Liss.Versailles, France:Google Scholar
  187. Muller, M. Renkawitz, R. 1991. The glucocorticoid receptor. Biochim Biophys Acta, 1088(2):171–182.PubMedGoogle Scholar
  188. Mundo, E., et al. 2001. The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder. Arch Gen Psychiatr, 58:539–544.PubMedGoogle Scholar
  189. Murphy, G., et al. Effects of the serotonin transporter promoter polymorphism on paroxetine and mirtazapine efficacy and side effects in geriatric major depression. in Pharmacogenetics in psychiatry meeting. 2003. New York.Google Scholar
  190. Murphy, G.M., Jr et al. 2003. Pharmacogenetics of Antidepressant Medication Intolerance. Am J Psychiatr, 160(10):1830–1835.PubMedGoogle Scholar
  191. Murphy, G.M., Jr et al. 2004. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression Arch Gen Psychiatr, 61(11):1163–1169.PubMedGoogle Scholar
  192. Myers, R.L., et al. 2006. Polymorphisms in the regulatory region of the human serotonin 5-HT(2A) receptor gene (HTR2A) influence gene expression. Biol Psychiatr, 11. Google Scholar
  193. Nebert, D. Dieter, M. 2002. The evolution of drug metabolism. Pharmacology, 61(3):124–135.Google Scholar
  194. Nemeroff, C.B., et al. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science, 226(4680):1342–1344.PubMedGoogle Scholar
  195. Nemeroff, C.B., et al. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatr, 45(6):577–579.PubMedGoogle Scholar
  196. Newman, T.K., et al. 2005. Monoamine oxidase A gene promoter variation and rearing experience influences aggressive behavior in rhesus monkeys. Biol Psychiatr, 57(2):167–172.Google Scholar
  197. Newton, R.A., et al. 1996. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J Neurochem, 67(6):2521–2531.PubMedGoogle Scholar
  198. Niculescu, A.B., et al. 2000. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genom, 4(1):83–91.Google Scholar
  199. Nierenberg, A.A., 2003. Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am, 26:345–352.PubMedGoogle Scholar
  200. Nobile, M., et al. 2004. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatr, 56(4):292–295.Google Scholar
  201. Nutt, D., 1998. Substance-P antagonists: a new treatment for depression? Lancet, 352(9141):1644–1646.PubMedGoogle Scholar
  202. O’Reilly, R.L., Bogue, L. Singh, S.M. 1994. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatr, 36(7):467–471.Google Scholar
  203. Ogilvie, A.D., et al. 1996. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet, 347:731–733.PubMedGoogle Scholar
  204. Ohara, K., et al. 2003. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol, 58(10):659–661.PubMedGoogle Scholar
  205. Okamura, K., et al. 2005. Lack of an association between 5-HT receptor gene polymorphisms and suicide victims. Psychiatr Clin Neurosci, 59(3):345–349.Google Scholar
  206. Olsavsky, K.M., et al. 2007. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol, 222(1):42–56.PubMedGoogle Scholar
  207. Overstreet, D. Griebel, G. 2004. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol, 497(1):49–53.PubMedGoogle Scholar
  208. Ozdemir, V., Tyndale, R. Reed, K. 1999. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol, 19(5):472–475.PubMedGoogle Scholar
  209. Pae, C.U., et al. 2007. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics Genomics, 17(1):69–75.Google Scholar
  210. Park, J.W., et al. 2004. Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache, 44(10):1005–1009.PubMedGoogle Scholar
  211. Parsian, A., 1999. Sequence analysis of exon 8 of MAO-A gene in alcoholics with antisocial personality and normal controls. Genomics, 55(3):290–295.PubMedGoogle Scholar
  212. Paul, I.A., 2001. Antidepressant activity and calcium signaling cascades. Hum Psychopharmacol, 16(1):71–80.PubMedGoogle Scholar
  213. Perez, V., et al. 1997. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment Lancet, 349:1594–1597.PubMedGoogle Scholar
  214. Perlis, R.H., et al. 2003. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatr, 54(9):879–883.Google Scholar
  215. Perlis, R.H., 2007. Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am, 30: (1):125–138.PubMedGoogle Scholar
  216. Peters , E.J., et al., Investigation of serotonin-related genes in antidepressant response. Mol Psychiatr, 2004.Google Scholar
  217. Pociot, F., et al. 1992. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest, 22(6):396–402.PubMedGoogle Scholar
  218. Pollock, B.G., et al. 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology, 23(5):587–590.PubMedGoogle Scholar
  219. Popp, J., et al. 2006. Serotonin transporter polymorphisms and side effects in antidepressant therapy–a pilot study. Pharmacogenomics, 7(2):159–166.PubMedGoogle Scholar
  220. Preisig, M., Ferrero, F. Malafosse, A. 2005. Monoamine oxidase a and tryptophan hydroxylase gene polymorphisms: are they associated with bipolar disorder? Am J Pharmacogenomics, 5(1):45–52.PubMedGoogle Scholar
  221. Raadsheer, F.C., et al. 1994. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology, 60(4):436–444.PubMedGoogle Scholar
  222. Rada, P., et al. 1991. Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res, 550(2):287–290.PubMedGoogle Scholar
  223. Ramamoorthy, S., et al. 1993. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization Proc Natl Acad Sci U S A, 90(6):2542–2546.PubMedGoogle Scholar
  224. Rao, N., 2007. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet, 46(4):281–290.PubMedGoogle Scholar
  225. Rau, T., et al. 2004. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther, 75(5):386–393.PubMedGoogle Scholar
  226. Rausch, J.L., et al. 2002. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatr, 51(9):723–732.Google Scholar
  227. Reppert, S.M. Weaver, D.R. 2002. Coordination of circadian timing in mammals. Nature, 418(6901):935–941.PubMedGoogle Scholar
  228. Rigat, B., et al. 1990. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest, 86(4):1343–1346.PubMedGoogle Scholar
  229. Roberts, R.L., et al. 2002. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J, 2(3):191–196.PubMedGoogle Scholar
  230. Rosskopf, D., et al. 2000. G protein beta 3 gene: structure, promoter, and additional polymorphisms. Hypertension, 36(1):33–41.PubMedGoogle Scholar
  231. Rousseva, A., et al. 2003. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J, 3(2):101–104.PubMedGoogle Scholar
  232. Ruiz-Velasco, V. Ikeda, S.R. 2003. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genomics, 13(2):85–95.PubMedGoogle Scholar
  233. Rujescu, D., et al. 2003. Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatr, 54(4):465–473.Google Scholar
  234. Sabol, S.Z., Hu, S. Hamer, D. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Human Genetic, 103:273–279.Google Scholar
  235. Sakai, K., et al. 1998. The genomic organization of the human corticotropin-releasing factor type-1 receptor. Gene, 219(1–2):125–130.PubMedGoogle Scholar
  236. Sakowski, S.A., et al. 2006. Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res, 1085(1):11–18.PubMedGoogle Scholar
  237. Sato, K., et al. 2002. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology, 46(3):136–140.PubMedGoogle Scholar
  238. Scheuch , K., et al., Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatr, 2007.Google Scholar
  239. Scordo, M.G., et al. 2005. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol, 97(5):296–301.PubMedGoogle Scholar
  240. Sei, H., et al. 2006. Clock mutant mice with Jcl/ICR background shows an impaired learning ability in water maze, but not in passive avoidance, at the beginning of dark phase. Congenit Anom (Kyoto), 46(2):81–85.Google Scholar
  241. Serretti, A., et al. 1998. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatrica Scandinavica, 98(6):443–450.PubMedGoogle Scholar
  242. Serretti, A., et al. 1999. Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. Psychiatr Res, 89:107–114.Google Scholar
  243. Serretti, A., et al. 2001a. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatr, 6:586–592.Google Scholar
  244. Serretti, A., et al. 2001b. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatr Res, 104(3):195–203.Google Scholar
  245. Serretti, A., et al. 2001c. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol, 11(5):375–380.Google Scholar
  246. Serretti, A., et al. 2003a. Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism Am J Med Genet, 121B(1):39–43.Google Scholar
  247. Serretti, A., et al. 2003b. SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol, 13(2):117–122.Google Scholar
  248. Serretti, A., et al. 2004a. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet, 129(1):36–40.Google Scholar
  249. Serretti, A., et al. 2004b. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl), 174(4):504–511.Google Scholar
  250. Serretti, A., et al. 2004c. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. Pharmacogenetics, 14(9):607–613.Google Scholar
  251. Serretti, A., et al. 2004d. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol, 7(4):453–460.Google Scholar
  252. Serretti, A., et al. 2005a. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet, 10:10.Google Scholar
  253. Serretti, A., et al. 2005b. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatr, 29(6):1074–1084.Google Scholar
  254. Serretti, A., et al. 2006b. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets, 7(12):1659–1669.Google Scholar
  255. Serretti, A., et al. 2006b. Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms Neuropsychobiology, 53(1):9–16.Google Scholar
  256. Serretti, A., et al. 2007a. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatr, 12(3):247–257.Google Scholar
  257. Serretti, A., et al. 2007b. Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatr Res, 149(1–3):185–193.Google Scholar
  258. Seymour, P., Schmidt, A. Schulz, D. 2003. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev, 9(1):57–96.PubMedGoogle Scholar
  259. Shams, M.E., et al. 2006. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther, 31(5):493–502.PubMedGoogle Scholar
  260. Shang, Y., et al. 2007. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol, 27(1):71–75.PubMedGoogle Scholar
  261. Shintani, F., et al. 1993. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci, 13(8):3574–3581.PubMedGoogle Scholar
  262. Shirayama, Y., et al. 1996. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res, 739(1–2):70–78.PubMedGoogle Scholar
  263. Siffert, W., et al. 1998. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet, 18(1):45–48.PubMedGoogle Scholar
  264. Sims, K.B., et al. 1989. Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron, 2(1):1069–1076.PubMedGoogle Scholar
  265. Skrebuhhova, T., Allikmets, L. Matto, V. 1999. Effects of anxiogenic drugs in rat forced swimming test. Meth Find Exp Clin Pharmacol, 21(3):173–178.Google Scholar
  266. Smeraldi, E., et al. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatr, 3(6):508–511.Google Scholar
  267. Smeraldi, E., et al. 2006. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet, 16(4):153–158.PubMedGoogle Scholar
  268. Smith, D.A., et al. 1998. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica, 28(12):1095–1128.PubMedGoogle Scholar
  269. Smith, G., et al. 1998. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 28(12):1129–1165.PubMedGoogle Scholar
  270. Smits, K., et al. 2007. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol, 22(3):137–143.PubMedGoogle Scholar
  271. Smits, K.M., et al. 2004. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatr, 9(5):433–441.Google Scholar
  272. Smits, K.M., et al. 2007. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin Ther, 29(4):691–702.PubMedGoogle Scholar
  273. Spurlock, G., et al. 1998. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatr, 3(1):42–49.Google Scholar
  274. Steeves, T.D., et al. 1999. Molecular cloning and characterization of the human clock gene: mexpression in the suprachiasmatic nuclei. Genomics, 57:198–200.Google Scholar
  275. Steiger, H., et al. 2005. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes Int J Eat Disord, 37(1):57–60.PubMedGoogle Scholar
  276. Steimer, W., et al. 2005. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem, 51(2):376–385.PubMedGoogle Scholar
  277. Stockmeier, C.A., et al. 1998. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci, 18(18):7394–7401.PubMedGoogle Scholar
  278. Sugai, T., et al. 2006. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J, 6(5):351–356.PubMedGoogle Scholar
  279. Suzuki, E., et al. 2003. Long-term imipramine treatment increases nitrate levels in the rat hypothalamus. Cell Mol Neurobiol, 23(6):953–962.PubMedGoogle Scholar
  280. Suzuki, Y., Sawamura, K. Someya, T. 2004. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics J, 4(4):283–286.Google Scholar
  281. Suzuki, Y., Sawamura, K. Someya, T. 2006. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology, 31(4):825–831.PubMedGoogle Scholar
  282. Svenningsson, P., et al. 2007. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci, 27(15):4201–4209.PubMedGoogle Scholar
  283. Szegedi, A., et al. 2005. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J, 5(1):49–53.PubMedGoogle Scholar
  284. Tadic, A., et al. 2007. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet, 144(3):325–331.Google Scholar
  285. Takahashi, H., et al. 2002. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol, 12(5):477–481.PubMedGoogle Scholar
  286. Thuerauf, N. Lunkenheimer, J. 2006. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatr Clin Neurosci, 256(5):287–293.Google Scholar
  287. Trent, J.M. Witkowski, C.M. 1987. Clarification of the chromosomal assignment of the human P-glycoprotein/mdr1 gene: possible coincidence with the cystic fibrosis and c-met oncogene. Cancer Genet Cytogenet, 26(1):187–190.PubMedGoogle Scholar
  288. Tringali, G., et al. 1996. Evidence for the neuronal origin of immunoreactive interleukin-1 beta released by rat hypothalamic explants. Neurosci Lett, 219(3):143–146.PubMedGoogle Scholar
  289. Tsai, S.J., et al. 2004. Association study of serotonin 1B receptor (A-161T) genetic polymorphism and suicidal behaviors and response to fluoxetine in major depressive disorder. Neuropsychobiology, 50(3):235–238.PubMedGoogle Scholar
  290. Usiello, A., et al. 2000. Distinct functions of the two isoforms of dopamine D2 receptors. Nature, 408(6809):199–203.PubMedGoogle Scholar
  291. Uz, T., et al. 2005. Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience, 134(4):1309–1316.PubMedGoogle Scholar
  292. Weide, J., van der Baalen-Benedek, E.H. van Kootstra-Ros, J.E. 2005. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit, 27(4):478–483.PubMedGoogle Scholar
  293. Pett, K., Van et al. 2000. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol, 428(2):191–212.PubMedGoogle Scholar
  294. Rossum, E.F., van et al. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatr, 59(8):681–688.Google Scholar
  295. Tol, H.H., Van et al. 1991. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350(6319):610–614.PubMedGoogle Scholar
  296. Veefkind, A., Haffmans, Hoencamp, E. 2000. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit, 22(2):202–208.Google Scholar
  297. Vilar, R., et al. 2007. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson’s disease. Eur J Neurol, 14(2):156–161.PubMedGoogle Scholar
  298. Wegener, G., et al. 2003. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res, 959(1):128–134.PubMedGoogle Scholar
  299. Weinshilboum, R.M., Otterness, D.M. Szumlanski, C.L. 1999. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol, 39:19–52.PubMedGoogle Scholar
  300. Wendland, J.R., et al. 2006. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531 Mol Psychiatr, 11(3):224–226.Google Scholar
  301. Wendland, J.R., et al., A Large Case-Control Study of Common Functional SLC6A4 and BDNF Variants in Obsessive-Compulsive Disorder. Neuropsychopharmacology, 2007.Google Scholar
  302. Wesolowska, A. Nikiforuk, A. 2007. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology, 52(5):1274–1283.PubMedGoogle Scholar
  303. Wess, J., 1998. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther, 80(3):231–264.PubMedGoogle Scholar
  304. Wilkie, M.J., et al. 2007. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics, 17(3):207–215.PubMedGoogle Scholar
  305. Willner, P., Hale, A.S. Argyropoulos, S. 2005. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord, 86(1):37–45.PubMedGoogle Scholar
  306. Wu, W.H., et al. 2001. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology, 44(4):172–175.PubMedGoogle Scholar
  307. Xu, J., et al. 2003. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem, 278(12):10770–10777.PubMedGoogle Scholar
  308. Xu, W., et al. 1993. Regional localization of the gene coding for human brain nitric oxide synthase (NOS1) to 12q24.2‐‐>24.31 by fluorescent in situ hybridization. Cytogenet Cell Genet, 64(1):62–63.PubMedGoogle Scholar
  309. Yamauchi, M., et al., Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res, 2005:164–169.Google Scholar
  310. Yan, Z. Wu, Y. 2007. [Relation between cytochrome P450 2D6 and lung cancer susceptibility caused by smoking]. Wei Sheng Yan Jiu, 36(1):112–3, 116.PubMedGoogle Scholar
  311. Yang, K., et al. 2007. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatr, 41(3):266–273.Google Scholar
  312. Yang-Feng, T.L., et al. 1990. Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci U S A, 87(4):1516–1520.PubMedGoogle Scholar
  313. Yatham, L.N., et al. 1999. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment – A positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatr, 56(8):705–711.PubMedGoogle Scholar
  314. Yeo, A., et al. 2004. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut, 53(10):1452–1458.PubMedGoogle Scholar
  315. Yin, O.Q., et al. 2006. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol, 26(4):367–372.PubMedGoogle Scholar
  316. Yoshida, K., et al. 2002. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatr, 26(2):383–386.Google Scholar
  317. Yoshida, K., et al. 2002. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder Prog Neuropsychopharmacol Biol Psychiatr, 26(7–8):1279–1283.Google Scholar
  318. Yoshida, K., et al. 2003. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology, 48(1):10–13.PubMedGoogle Scholar
  319. Yoshida, K., et al. 2004. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatr, 161(9):1575–1580.PubMedGoogle Scholar
  320. Yu, Y., et al., Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology, 2005. 30(1719–1723).Google Scholar
  321. Yu, Y.W., et al. 2002. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatr, 7(10):1115–1119.Google Scholar
  322. Yu, Y.W., et al. 2003a. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology, 47(3):137–140.Google Scholar
  323. Yu, Y.W., et al. 2003b. Association study of the interleukin-1beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology, 28(6):1182–1185.Google Scholar
  324. Yu, Y.W., et al. 2006. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol, 16(7):498–503.PubMedGoogle Scholar
  325. Zanardi, R., et al. 2000. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol, 20(1):105–107.PubMedGoogle Scholar
  326. Zanardi, R., et al. 2001. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatr, 50(5):323–330.Google Scholar
  327. Zangen, A., et al. 2001. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl), 155(4):434–439.Google Scholar
  328. Zateyshchikov, D.A., et al. 2007. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol, 21(4):437–443.PubMedGoogle Scholar
  329. Zeise, M.L., Madamba, S. Siggins, G.R. 1992. Interleukin-1 beta increases synaptic inhibition in rat hippocampal pyramidal neurons in vitro. Regul Pept, 39(1):1–7.PubMedGoogle Scholar
  330. Zhang, X., et al. 2004. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science, 305(5681):217.PubMedGoogle Scholar
  331. Zhang, X., et al., Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron, 2005. 45(11–16).Google Scholar
  332. Zhou, Z. et al. 2005. Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatr, 62(10):1109–1118.PubMedGoogle Scholar
  333. Zill, P., et al. 2000. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport, 11(9):1893–1897.PubMedGoogle Scholar
  334. Zill, P., et al. 2003. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response. Am J Med Genet, 120B(1):85–89.PubMedGoogle Scholar
  335. Zill, P., et al. 2004a. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatr, 56(8):581–586.Google Scholar
  336. Zill, P., et al. 2004b. The dysbindin gene in major depression: an association study. Am J Med Genet B Neuropsychiatr Genet, 129(1):55–58.Google Scholar
  337. Zill , P., et al., Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. J Psychiatr Res, 2005: [Epub ahead of print].Google Scholar
  338. Zorrilla, E.P., et al. 2001. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun, 15(3):199–226.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Institute of PsychiatryUniversity of BolognaItaly

Personalised recommendations